Ordering Recommendation

Aids in monitoring but is not recommended for diagnosis of carcinoid tumors. May be useful in monitoring nonsecretory sympathetic and parasympathetic neuroendocrine tumors.

Mnemonic
CGA
Methodology

Immunofluorescence

Performed

Mon, Wed, Fri, Sun

Reported

1-5 days

New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
Collect

Serum separator tube or plain red.

Specimen Preparation

Allow serum specimen to clot completely at room temperature. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature

Frozen.

Unacceptable Conditions

Plasma.

Remarks
Stability

After separation from cells: Ambient: 48 hours; Refrigerated: 3 days; Frozen: 4 weeks

Reference Interval

0-103 ng/mL

Interpretive Data

This test is performed using the BRAHMS CGA II Kryptor kit. Results obtained with different methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.

Nontumor-related elevations of Chromogranin A can be observed in gastrointestinal, cardiovascular, and renal disorders, as well as with proton pump inhibitor (PPI) therapy. It is recommended to stop PPI treatment for at least two weeks prior to testing. Moderate H2-receptor antagonist therapy does not lead to significant elevations of Chromogranin A.

Compliance Category

Laboratory Developed Test (LDT)

Note
Hotline History
N/A
CPT Codes

86316

Components
Component Test Code* Component Chart Name LOINC
3002868 Chromogranin in serum 9811-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • CgA
Chromogranin A, Serum